FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including a method for administering a therapeutic protein to a subject according to a dosing schedule to reduce the incidence or severity of cytokine release syndrome or an infusion reaction in the treatment of CD20-expressing B-cell lymphoma (versions) and a method of the treatment of CD20-expressing B-cell lymphoma in a subject.
EFFECT: invention expands the arsenal of methods of the treatment of CD20-expressing B-cell lymphoma.
84 cl, 1 dwg, 10 tbl, 2 ex
| Title |
Year |
Author |
Number |
| PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING AND/OR TREATING A DISEASE THAT DEVELOPS OR PROGRESSES AS A RESULT OF REDUCING OR LOSING ACTIVITY OF THE BLOOD COAGULATION FACTOR VIII AND/OR ACTIVATED COAGULATION FACTOR VIII |
2015 |
|
RU2721910C2 |
| HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING SPECIFIC GROUPS OF INDIVIDUALS |
2012 |
- Hanotin, Corinne
- Bessac, Laurence
- Chaudhari, Umesh
|
RU2721279C2 |
| ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE |
2019 |
- Beaumont, Kevin Charles
- Breen, Danna M.
- Chabot, Jeffrey Raymond
- He, Tao
- Shchors, Ksenya
- Apgar, James R.
- Lambert, Matthew Allister
|
RU2795457C2 |
| ANTIBODIES SUITABLE FOR PASSIVE IMMUNIZATION AGAINST INFLUENZA, AND COMPOSITIONS THEREOF, COMBINATIONS AND METHODS OF USING |
2015 |
- Estelles Andzheles
- Kauvar Lourens M.
- Vigil Adam
- Vittekind Majkl
|
RU2720282C1 |
| METHODS FOR TREATMENT OF HYPERLIPIDEMIA IN PATIENTS WITH DIABETES BY INJECTION OF PCSK9 INHIBITOR |
2018 |
|
RU2772712C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF |
2020 |
- Makdonakh, Sharlott Fenton
- Panvar, Radzhiv
- Khekhler, Torsten
- Kulke, Mikhael
- Sarma, Ganapati N.
- Pal, Andreas
- Myuller, Kristof
- Simon, Verner
- Lutts, Kristian
- Gallo, Francheska
|
RU2826004C2 |
| USE OF ANTIBODIES TO SCLEROSTIN FOR TREATING OSTEOGENESIS IMPERFECTA |
2017 |
- Yunker, Uve
- Knejssel, Mikhaela
- Kholl, Entoni Kent
- Eudi, Rena Dzhoj
- Riggs, Mettyu Menning
|
RU2789033C2 |
| ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR AND THEIR USE |
2016 |
- Apgar Dzhejms R.
- Benard Syuzan
- Karven Gregori Dzh.
- Khett Sanita R.
- Kholsti Mettyu
- Dzhasudzha Reema
- Dzhin Mejsi
- Tszyuo Chzhon Shon
- Pittman Debra
- Stal Mark
|
RU2815681C1 |
| STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE |
2018 |
- De, Arnab
- Narasimkhan, Chakravarti Nachu
|
RU2820576C2 |
| METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES |
2019 |
- Lala, Mallika
- Dzhejn, Lokesh
- Li, Mengiao
- Altura, Rejchel Ellison
- Tse, Archi Ngaj-Chiu
|
RU2825835C2 |
